SCHEMBL7538016

SCHEMBL7538016

[C]OCc1cccc2c1Cc1ccccc1-2

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNMT P11086 1/20 0.62
DRD2 P14416 3/20 0.45
DRD4 P21917 3/20 0.45
DRD3 P35462 3/20 0.45
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
HTR7 P34969 1/20 0.37
HTR2B P41595 1/20 0.37
MAOA P21397 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA4 P22748 1/20 0.34
CA6 P23280 1/20 0.34
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 2/20 0.34
MAPT P10636 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3979804 0.83 PNMT (0.67) PNMTDRD2DRD4DRD3NPC1
SCHEMBL456019 0.83 PNMT (0.62) PNMTDRD2DRD4DRD3NPC1
SCHEMBL21359984 0.80 PNMT (0.58) PNMTDRD2DRD4DRD3NPC1
SCHEMBL1275883 0.80 PNMT (0.58) PNMTDRD2DRD4DRD3NPC1
SCHEMBL7195192 0.80 PNMT (0.72) PNMTDRD2DRD4DRD3NPC1
SCHEMBL5366733 0.80 PNMT (0.72) PNMTDRD2DRD4DRD3NPC1
SCHEMBL7765 0.79 PNMT (0.57) PNMTDRD2DRD4DRD3NPC1
SCHEMBL22588781 0.79 PNMT (0.57) PNMTDRD2DRD4DRD3NPC1
SCHEMBL31346823 0.79 PNMT (0.57) PNMTDRD2DRD4DRD3NPC1
SCHEMBL1830397 0.79 PNMT (0.57) PNMTDRD2DRD4DRD3NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3416730-A1 DERMATOLOGICAL COSMETIC COMPOSITION COMPRISING AN SDKP PEPTIDE OR AN ANALOG THEREOF RPM Dermatologie (FR) 2018-12-26 EP disclosed
WO-2002032974-A2 POLYMER AND ITS USE FOR THE TREATMENT AND/OR PREVENTION OF HYPERPHOSPHOREMIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-04-25 WO disclosed
EP-0772451-A4 TREATMENT OF TYPE II DIABETES MELLITUS WITH AMYLIN AGONISTS AMYLIN PHARMACEUTICALS INC (US) 1998-09-30 EP disclosed
EP-0772451-A1 TREATMENT OF TYPE II DIABETES MELLITUS WITH AMYLIN AGONISTS AMYLIN PHARMACEUTICALS, INC. (US) 1997-05-14 EP disclosed
WO-1996040220-A1 TREATMENT OF TYPE II DIABETES MELLITUS WITH AMYLIN AGONISTS AMYLIN PHARMACEUTICALS, INC. (US) 1996-12-19 WO disclosed
EP-0532746-A4 ASSAY FOR NON-A NON-B HEPATITIS 1993-07-21 EP disclosed
EP-0532746-A1 ASSAY FOR NON-A NON-B HEPATITIS. BAXTER DIAGNOSTICS INC (US) 1993-03-24 EP disclosed
WO-1992017612-A1 ASSAY FOR NON-A NON-B HEPATITIS BAXTER DIAGNOSTICS INC. (US) 1992-10-15 WO disclosed